<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22303" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Glucagon</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Morris</surname>
            <given-names>Caleb H.</given-names>
          </name>
          <aff>Central Michigan University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Baker</surname>
            <given-names>Japheth</given-names>
          </name>
          <aff>Magnolia Regional Health Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Caleb Morris declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Japheth Baker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22303.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Glucagon, a member of the anti-hypoglycemic class of medications, is crucial in managing diverse medical scenarios. This medication is employed to address acute hypoglycemia, offering an option for treating overdoses of beta-blockers and calcium channel blockers. Its efficacy&#x000a0;includes&#x000a0;refractory anaphylaxis cases not responsive to epinephrine, showcasing its versatility in critical situations. Moreover, glucagon serves as a valuable intervention in cases of esophageal obstruction caused by food bolus impaction, aiding healthcare professionals in facilitating the passage of such obstructions.</p>
        <p>This activity explores the indications and contraindications of glucagon, shedding light on its pharmacological attributes, potential adverse events, off-label applications, optimal dosing strategies, and the crucial monitoring required. The&#x000a0;course encompass relevant interactions, equipping interprofessional healthcare team members with the necessary insights for managing patients requiring glucagon in various clinical contexts.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for glucagon administration in various clinical scenarios, including severe hypoglycemia, beta-blocker overdose, calcium channel blocker overdose, and esophageal food impaction.</p></list-item><list-item><p>Screen patients to determine their eligibility for glucagon therapy based on their medical history, allergies, and potential contraindications.</p></list-item><list-item><p>Assess the patient's response to glucagon therapy and monitor for adverse effects or complications.</p></list-item><list-item><p>Determine methods&#x000a0;with pharmacists and other healthcare professionals to optimize the use of glucagon and address any drug-drug interactions or medication-related concerns.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22303&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22303">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22303.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Glucagon is a polypeptide hormone commonly used in the treatment of severe hypoglycemia.&#x000a0;Glucagon is FDA-approved for the treatment of severe hypoglycemia. Severe hypoglycemia is a life-threatening event treated with oral carbohydrate intake, IV glucose, or glucagon by various routes. Glucagon has attractive traits in the diabetic population due to its simplicity of use and safe administration, not requiring patent IV access.<xref ref-type="bibr" rid="article-22303.r1">[1]</xref></p>
        <p>Patients with decreased levels of consciousness cannot safely consume the oral carbohydrates needed to raise their blood sugar without risk of aspiration, and obtaining IV access can be problematic in the diabetic population, preventing prompt administration of IV glucose. IV glucose increases the risk of severe tissue necrosis in IV medication extravasation. Glucagon is a reliable method of raising the patient's glucose and relieving severe hypoglycemia long enough for more definitive correction of the patient's glucose levels by mouth, mainly when IV access is unavailable to the provider or has failed.<xref ref-type="bibr" rid="article-22303.r1">[1]</xref></p>
        <p>Glucagon is FDA-approved as a diagnostic aid&#x000a0;during&#x000a0;imaging of the GI tract. Glucagon's role in gastrointestinal imaging is to induce bowel and upper gastrointestinal tract hypotonia, which permits more precise visualization for studies and procedures; this is the same mechanism by which it helps esophageal food boluses pass. The primary indicated use is to decrease peristalsis during abdominal vascular procedures such as treating esophageal varices and other GI bleeds. Glucagon is also utilized in biopsies, abscess drainage, GI stenting, and gastrostomy tube placement. Previously, radiologists used anticholinergic agents for the same indication but switched to glucagon in the 1970s due to a safer side effect profile.<xref ref-type="bibr" rid="article-22303.r2">[2]</xref><xref ref-type="bibr" rid="article-22303.r3">[3]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Glucagon has several off-label indications, including beta-blocker overdose therapy, calcium channel blocker overdose adjunctive therapy, and medical treatment of esophageal food impaction. Beta-blocker overdose and calcium channel blocker overdose can be treated with high-dose glucagon infusion in addition to beta-agonists such as epinephrine. Because of the logistical difficulties associated with obtaining large amounts of glucagon needed for infusion, the recommendation is that high-dose insulin euglycaemic therapy (HIET) and catecholamine therapy be optimized before adding glucagon infusion, unless readily available in adequate quantities. Calcium channel blocker overdose can also receive treatment with glucagon; glucagon is a second-line therapy behind calcium, epinephrine, high-dose insulin, and dextrose.<xref ref-type="bibr" rid="article-22303.r4">[4]</xref><xref ref-type="bibr" rid="article-22303.r5">[5]</xref></p>
        <p>Glucagon's indications have continued to develop since its discovery. Research is ongoing to treat asthmatic bronchospasm as a constituent in the bi-hormonal artificial pancreas, as well as more traditional insulin and arrhythmias secondary to cardiac anaphylaxis.<xref ref-type="bibr" rid="article-22303.r6">[6]</xref><xref ref-type="bibr" rid="article-22303.r7">[7]</xref><xref ref-type="bibr" rid="article-22303.r8">[8]</xref></p>
      </sec>
      <sec id="article-22303.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Glucagon binds G-coupled surface receptors found throughout the body in varying concentrations,&#x000a0;binding to the glucagon receptors in the liver, GI tract, heart, pancreas, fat, adrenal glands, and kidneys to activate adenylate cyclase, which raises cAMP levels.&#x000a0;cAMP stimulates glycogenolysis and glucogenesis, resulting in the release of glucose, primarily from liver glycogen stores. The extrahepatic effects of glucagon are also mediated by adenylate cyclase, including relaxation of GI smooth muscle and positive inotropic effects.<xref ref-type="bibr" rid="article-22303.r9">[9]</xref><xref ref-type="bibr" rid="article-22303.r10">[10]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Glucagon, when administered subcutaneously, reaches peak plasma concentration (3533 pg/mL) in 10&#x000a0;to 13 minutes. When glucagon 1 mg is administered intramuscularly, it&#x000a0;reaches peak plasma concentration (3391 pg/mL) in 10 minutes.</p>
        <p><bold>Metabolism:</bold> Glucagon is metabolized in the liver, kidney, and plasma.</p>
        <p><bold>Elimination:</bold> The mean half-life of glucagon is approximately 42 minutes following subcutaneous administration and 26&#x000a0;minutes following intramuscular administration.</p>
        <p>
<bold>Pharmacodynamics</bold>
</p>
        <p><bold>Intravenous:</bold> Glucagon, administered IV (0.25 mg to 0.5 mg), reaches maximum glucose concentration in 5&#x000a0;to 20 minutes. Glucagon produces GI smooth muscle relaxation, with an onset of 45 seconds and a duration of smooth muscle relaxation from 9&#x000a0;to 17 minutes.</p>
        <p><bold>Intramuscular:</bold> Glucagon, when injected IM (1 mg), reaches maximum glucose concentration in 30 minutes. Glucagon produces GI smooth muscle relaxation, with an onset of 8 to 10 minutes and a duration of smooth muscle relaxation from 12 to 27 minutes.&#x000a0;Glucagon, when injected with IM (2 mg), reaches maximum glucose concentration in 30 minutes&#x000a0;and produces GI smooth muscle relaxation onset in 4 to 7 minutes and&#x000a0;duration of smooth muscle relaxation from 21 to 32 minutes.</p>
      </sec>
      <sec id="article-22303.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms</bold>
</p>
        <p>Glucagon can be administered intravenously as a bolus or infusion, intramuscularly, subcutaneously, and intranasally. Glucagon is available as a dehydrated powder termed a "Glucagon&#x000a0;Emergency Kit," which is reconstituted with supplied sterile water or as a purpose-formulated intranasal spray. Like epinephrine auto-injectors, a&#x000a0;pre-filled glucagon injector has received approval to inject glucagon into the patient's thigh.</p>
        <p>Healthcare providers often encounter the emergency kit formulation necessitating reconstitution before injecting the medication. Still, the intranasal spray may be encountered with increasing frequency in hypoglycemia kits for layperson use. The intranasal powder requires no preparation, and administration is via a spray into the patient's nose while holding the other nostril closed.<xref ref-type="bibr" rid="article-22303.r11">[11]</xref><xref ref-type="bibr" rid="article-22303.r12">[12]</xref></p>
        <p>It is available on the market in injections of 1 mg glucagon, subcutaneous injection solution 1 mg/0.2 mL; subcutaneous auto-injector solution 0.5 mg/0.1 mL, 1 mg/0.2 mL; subcutaneous solution in pre-filled syringe 0.5 mg/0.1 mL, 1 mg/0.2 mL; reconstituted solution for injection 1 mg/mL and nasal powder 3 mg/dose in a single dose and&#x000a0;2-dose pack. The unpunctured vials are suitable until the expiration date on the label, and after reconstitution, use the glucagon solution immediately and discard any unused portion.</p>
        <p>
<bold>Adult Dose</bold>
</p>
        <p><bold>Hypoglycemia:&#x000a0;</bold>&#x000a0;Administer 1 mg glucagon&#x000a0;intramuscularly, subcutaneously, or intravenously; repeat in 15 minutes if required or administer 3 mg (1 dose) intranasally into a single nostril; if no adequate response, can repeat the dose. Unconscious patients should be placed in a lateral recumbent position to prevent choking. When treating hypoglycemia, administer oral carbohydrates as soon as possible if the patient is conscious and responds to glucagon.<xref ref-type="bibr" rid="article-22303.r13">[13]</xref><xref ref-type="bibr" rid="article-22303.r14">[14]</xref></p>
        <p><bold>Radiologic Examinations as a Diagnostic Aid for Relaxation of the Colon:</bold> Administer 2 mg IM 10 minutes before the procedure.</p>
        <p><bold>Radiologic Examinations as a Diagnostic Aid for the Stomach, Duodenum, Duodenal Bulb, or Small Bowl:</bold> Administer a dose ranging between 0.25 mg to 2 mg IV over 1 minute or 1 mg to 2 mg IM as indicated.</p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold><bold>Hepatic impairment:</bold></bold>&#x000a0;No information is provided on the manufacturer's label regarding hepatic or renal impaired patients, including those on peritoneal or hemodialysis.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No information is provided on the manufacturer's label regarding hepatic or renal impaired patients, including those on peritoneal or hemodialysis.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Glucagon can be administered to treat hypoglycemia in pregnant patients with diabetes.<xref ref-type="bibr" rid="article-22303.r15">[15]</xref></p>
        <p><bold>Breastfeeding implications:</bold> There is no information about using glucagon in breastfeeding women. Because of its high molecular weight,&#x000a0;glucagon is secreted in low amounts in breast milk and can be destroyed by an infant's gastrointestinal tract. Glucagon has a good safety profile when administered directly to infants by injection, so no special precautions are needed.<xref ref-type="bibr" rid="article-22303.r16">[16]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;The safety and effectiveness of glucagon injections are established in pediatric patients with diabetes experiencing severe hypoglycemia. However, there is a lack of data on glucagon's use as a diagnostic aid during&#x000a0;radiologic examinations to inhibit the gastrointestinal tract's movement in pediatric patients temporarily.</p>
        <p><bold>Older patients:</bold>&#x000a0;No dosing restrictions are available for patients&#x000a0;older than 65.</p>
      </sec>
      <sec id="article-22303.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Nausea is the most frequently encountered adverse effect of glucagon administration, with an incidence as high as 35% in some studies.&#x000a0;Hypertension has been described up to 2 hours following administration for GI cases due to the inotropic effects of glucagon.&#x000a0;Additionally, severe anaphylactic reactions, including hypotension, rash, and vomiting, have been observed due to the protein structure.&#x000a0;Hypersensitivity reactions are rare; most have occurred in the endoscopic setting with IV administration.&#x000a0;Adverse reactions from glucagon administration become more likely with the IV route and when given higher doses.<xref ref-type="bibr" rid="article-22303.r14">[14]</xref><xref ref-type="bibr" rid="article-22303.r17">[17]</xref></p>
        <p>Less common adverse reactions include rebound hypoglycemia in the setting of insulinoma and worsening hyperglycemia in the setting of pancreatic glucagon-secreting tumors.&#x000a0;Additionally, the positive inotropic effects of glucagon can precipitate severe hypertension when administered to patients with pheochromocytoma. They should be avoided in favor of oral or IV glucose for emergency use and the clonidine suppression test for pheochromocytoma diagnosis.<xref ref-type="bibr" rid="article-22303.r18">[18]</xref></p>
      </sec>
      <sec id="article-22303.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The only absolute contraindication to glucagon administration is known hypersensitivity to the medication.&#x000a0;Most hypersensitivity reactions occur in GI imaging patients.<xref ref-type="bibr" rid="article-22303.r19">[19]</xref>&#x000a0;Relative contraindications include use in neonates or children, which may not have sufficient glycogen stores, and patients with known insulinoma, pheochromocytoma, or glucagon-secreting tumors.<xref ref-type="bibr" rid="article-22303.r20">[20]</xref><xref ref-type="bibr" rid="article-22303.r21">[21]</xref>&#x000a0;</p>
        <p>Patients with known lactose allergy (some dry powder inhalers contain lactose) should not use the formulation containing lactose.<xref ref-type="bibr" rid="article-22303.r22">[22]</xref></p>
      </sec>
      <sec id="article-22303.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring following glucagon injection should include blood pressure, heart rate, ECG, serial blood glucose checks, and signs of a hypersensitivity reaction. Monitoring is recommended for up to 2 hours after administration due to the medication's duration of action. Also, inform the patient and the care given on recognizing severe hypoglycemia with a detailed explanation of its signs and symptoms and the risk associated if left untreated.</p>
      </sec>
      <sec id="article-22303.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Administering doses of exogenous glucagon over the amount required can predictably result in adverse reactions requiring intervention. However, this is rare in the literature. Insulin antagonizes glucagon, but toxicity should not be treated with insulin in most circumstances. The transient hyperglycemia associated with glucagon administration is rarely life-threatening, and iatrogenic rebound hypoglycemia has a substantial risk of harm.&#x000a0;</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Treatment should focus on mitigating the hypertensive response to glucagon with alpha-blocking agents and vasodilators.<xref ref-type="bibr" rid="article-22303.r23">[23]</xref></p>
      </sec>
      <sec id="article-22303.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Glucagon may be necessary for treating various conditions, as discussed above, with hypoglycemic shock being the most common indication. The emergent nature of many of these indications necessitates the involvement of an interdisciplinary team led by various specialty clinicians, advised by a pharmacist, administered by nurses or paramedics, and monitored by nurses and lab technicians. Without intervention, morbidity and mortality from hypoglycemic shock and beta-blocker and calcium channel blocker overdoses are substantial.<xref ref-type="bibr" rid="article-22303.r1">[1]</xref>&#x000a0;</p>
        <p>Gastrointestinal imaging benefits from glucagon administration by improving image clarity and has been made safer by transitioning from anticholinergics to glucagon.<xref ref-type="bibr" rid="article-22303.r19">[19]</xref><xref ref-type="bibr" rid="article-22303.r24">[24]</xref>&#x000a0;</p>
        <p>The interprofessional healthcare team can enhance outcomes by coordinating care when physicians, advanced practice practitioners, nurses, laboratory technicians, and pharmacists work together to identify at-risk patients who may benefit from glucagon administration, often after failed first-line therapies or when first-line treatment is not immediately available. Pharmacists should be available to guide&#x000a0;whether to utilize glucagon and at what dosage, particularly given the high-stress environment in which this medication may be necessary. Pharmacist consultation has demonstrably increased the availability of glucagon to patients taking insulin.<xref ref-type="bibr" rid="article-22303.r25">[25]</xref>&#x000a0;</p>
        <p>Coordinated care of an interdisciplinary team would include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians ordering and nurses and technicians obtaining blood glucose levels</p>
          </list-item>
          <list-item>
            <p>Nurses and clinicians monitor the patient for signs of hypoglycemia, including tachycardia, diaphoresis, tremors, altered mentation, or coma.</p>
          </list-item>
          <list-item>
            <p>Ensuring the patient has ingested carbs and protein capable of preventing rebound hypoglycemia once capable of protecting their airway.
<list list-type="bullet"><list-item><p>Note: tachycardia may be absent in beta-blocker and calcium channel blocker overdoses.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Consulting a pharmacist regarding glucagon infusions in the setting of overdose.<xref ref-type="bibr" rid="article-22303.r5">[5]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Consulting a toxicologist for all glucagon therapy in the setting of overdose, additionally, engaging a toxicologist if an overdose of glucagon is suspected.</p>
          </list-item>
        </list>
        <p>Patients requiring prompt intervention with glucagon resulting from hypoglycemia, overdose, or imaging can be encountered throughout the hospital system and by the general public. Once the acute intervention has stabilized the patient,&#x000a0;preventing&#x000a0;a relapse of the condition is crucial, as glucagon's duration of action is likely shorter than the underlying cause of the emergency.</p>
        <p>Patients with diabetes experiencing hypoglycemic shock will likely require hospitalization but should also have a prompt follow-up with their endocrinologist or managing physician shortly after discharge. A caseworker and psychiatrist should be brought&#x000a0;in for suspected intentional overdoses. A coordinated interdisciplinary approach to patient care is generally necessary to improve patient safety and access and is essential in the safe treatment of patients with glucagon.</p>
      </sec>
      <sec id="article-22303.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22303&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22303">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22303/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22303">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22303.s11">
        <title>References</title>
        <ref id="article-22303.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kedia</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach.</article-title>
            <source>Diabetes Metab Syndr Obes</source>
            <year>2011</year>
            <volume>4</volume>
            <fpage>337</fpage>
            <page-range>337-46</page-range>
            <pub-id pub-id-type="pmid">21969805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Miscellaneous pharmaceutical agents in interventional radiology.</article-title>
            <source>Semin Intervent Radiol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>422</fpage>
            <page-range>422-30</page-range>
            <pub-id pub-id-type="pmid">22550384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreel</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pharmaco-radiology in barium examinations with special reference to glucagon.</article-title>
            <source>Br J Radiol</source>
            <year>1975</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>573</issue>
            <fpage>691</fpage>
            <page-range>691-703</page-range>
            <pub-id pub-id-type="pmid">810202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graudins</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Druda</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>453</fpage>
            <page-range>453-61</page-range>
            <pub-id pub-id-type="pmid">26344579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>19</issue>
            <fpage>1828</fpage>
            <page-range>1828-35</page-range>
            <pub-id pub-id-type="pmid">16990629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Khatib</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Balliro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hillard</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Magyar</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Ekhlaspour</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mondesir</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Esmaeili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hartigan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Malkani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lock</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Harlan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Clinton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>DeSalvo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Norlander</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Buckingham</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Diner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dezube</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Goley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirkman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Selagamsetty</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Damiano</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.</article-title>
            <source>Lancet</source>
            <year>2017</year>
            <month>Jan</month>
            <day>28</day>
            <volume>389</volume>
            <issue>10067</issue>
            <fpage>369</fpage>
            <page-range>369-380</page-range>
            <pub-id pub-id-type="pmid">28007348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Insuela</surname>
                <given-names>DBR</given-names>
              </name>
              <name>
                <surname>Azevedo</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Coutinho</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Magalh&#x000e3;es</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>TPT</given-names>
              </name>
              <name>
                <surname>Cascabulho</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Henriques-Pons</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>PMR</given-names>
              </name>
              <name>
                <surname>Cordeiro</surname>
                <given-names>RSB</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>VF</given-names>
              </name>
            </person-group>
            <article-title>Glucagon reduces airway hyperreactivity, inflammation, and remodeling induced by ovalbumin.</article-title>
            <source>Sci Rep</source>
            <year>2019</year>
            <month>Apr</month>
            <day>24</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>6478</fpage>
            <pub-id pub-id-type="pmid">31019244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andjelkovic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zlokovic</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Protective effects of glucagon during the anaphylactic response in guinea-pig isolated heart.</article-title>
            <source>Br J Pharmacol</source>
            <year>1982</year>
            <month>Jul</month>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>483</fpage>
            <page-range>483-9</page-range>
            <pub-id pub-id-type="pmid">6179557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Venugopal</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Physiology, Glucagon</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>6</day>
            <pub-id pub-id-type="pmid">30725767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Modulation of cAMP: mechanism for positive inotropic action.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>1986</year>
            <volume>8 Suppl 9</volume>
            <fpage>S22</fpage>
            <page-range>S22-9</page-range>
            <pub-id pub-id-type="pmid">2433539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dhingra</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intranasal Glucagon.</article-title>
            <source>J Pak Med Assoc</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>8</issue>
            <fpage>1219</fpage>
            <page-range>1219-1221</page-range>
            <pub-id pub-id-type="pmid">31431785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <article-title>In brief: A new glucagon injection (Gvoke) for severe hypoglycemia.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2019</year>
            <month>Nov</month>
            <day>18</day>
            <volume>61</volume>
            <issue>1585</issue>
            <fpage>186</fpage>
            <pub-id pub-id-type="pmid">31770360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reno</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Bendix Jensen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>T&#x000f6;r&#x000f6;k-Bath&#x000f3;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esdaile</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Pich&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Triest</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carballo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Needle-free nasal delivery of glucagon for treatment of diabetes-related severe hypoglycemia: toxicology of polypropylene resin used in delivery device.</article-title>
            <source>Cutan Ocul Toxicol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-7</page-range>
            <pub-id pub-id-type="pmid">26426957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rickels</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Ruedy</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Pich&#x000e9;</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Dulude</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sherr</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Tamborlane</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Bethin</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>DiMeglio</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Wadwa</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ahmann</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Marcovina</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rampakakis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <collab>T1D Exchange Intranasal Glucagon Investigators</collab>
            </person-group>
            <article-title>Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.</article-title>
            <source>Diabetes Care</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>264</fpage>
            <page-range>264-70</page-range>
            <pub-id pub-id-type="pmid">26681725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexopoulos</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Management of Preexisting Diabetes in Pregnancy: A Review.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>May</month>
            <day>14</day>
            <volume>321</volume>
            <issue>18</issue>
            <fpage>1811</fpage>
            <page-range>1811-1819</page-range>
            <pub-id pub-id-type="pmid">31087027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Glucagon</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>4</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">33886178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herskovitz</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Sendovski</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Severe allergic reaction to intravenous injection of glucagon.</article-title>
            <source>Radiology</source>
            <year>1997</year>
            <month>Mar</month>
            <volume>202</volume>
            <issue>3</issue>
            <fpage>879</fpage>
            <pub-id pub-id-type="pmid">9051052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elliott</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Straus</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Jarabak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Improved safety of glucagon testing for pheochromocytoma by prior alpha-receptor blockade. A controlled trial in a patient with a mixed ganglioneuroma/pheochromocytoma.</article-title>
            <source>Arch Intern Med</source>
            <year>1989</year>
            <month>Jan</month>
            <volume>149</volume>
            <issue>1</issue>
            <fpage>214</fpage>
            <page-range>214-6</page-range>
            <pub-id pub-id-type="pmid">2912409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paul</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Freyschmidt</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[The use glucagon for endoscopic and radiological examination of the gastrointestinal tract (author's transl)].</article-title>
            <source>Rofo</source>
            <year>1976</year>
            <month>Jul</month>
            <volume>125</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-7</page-range>
            <pub-id pub-id-type="pmid">133938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiesli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pfammatter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spinas</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia in response to glucose and glucagon in insulinoma patients with a negative prolonged fast: functional and morphological properties.</article-title>
            <source>J Endocrinol Invest</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>832</fpage>
            <page-range>832-8</page-range>
            <pub-id pub-id-type="pmid">15648547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hosseinnezhad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Adhikari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-induced pheochromocytoma crisis.</article-title>
            <source>Endocr Pract</source>
            <year>2011</year>
            <season>May-Jun</season>
            <volume>17</volume>
            <issue>3</issue>
            <fpage>e51</fpage>
            <page-range>e51-4</page-range>
            <pub-id pub-id-type="pmid">21324811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rashid</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Elgied</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alhamhoom</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rintoul</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Allahham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery.</article-title>
            <source>Pharmaceutics</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>11</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">31052466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Legler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-induced hypertensive emergency: a case report.</article-title>
            <source>J Clin Anesth</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>35</volume>
            <fpage>493</fpage>
            <page-range>493-496</page-range>
            <pub-id pub-id-type="pmid">27871582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Chernish</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Brunelle</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Gastrointestinal radiography with glucagon.</article-title>
            <source>Gastrointest Radiol</source>
            <year>1979</year>
            <month>Jan</month>
            <day>30</day>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">367874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22303.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Reilly</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kubiak</surname>
                <given-names>NT</given-names>
              </name>
            </person-group>
            <article-title>Impact of pharmacist intervention on glucagon prescribing patterns in an outpatient internal medicine teaching clinic.</article-title>
            <source>J Am Pharm Assoc (2003)</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>384</fpage>
            <page-range>384-390</page-range>
            <pub-id pub-id-type="pmid">31104980</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
